e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 87

Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen

Martin Michaelis; Bishr Agha; Florian Rothweiler; Nadine Löschmann; Yvonne Voges; Michel Mittelbronn; Tatjana Starzetz; Patrick N. Harter · 2015 · Scientific Reports

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Flubendazole was shown to exert anti-leukaemia and anti-myeloma activity through inhibition of microtubule function. Here, flubendazole was tested for its effects on the viability of in total 461 cancer cell lines. Neuroblastoma was identified as highly flubendazole-sensitive cancer entity in a screen of 321 cell lines from 26 cancer entities. Flubendazole also reduced the viability of five primary neuroblastoma samples in nanomolar concentrations thought to be achievable in humans and inhibited vessel formation and neuroblastoma tumour growth in the chick chorioallantoic membrane assay. Resis

Abstract by Martin Michaelis; Bishr Agha; Florian Rothweiler; Nadine Löschmann; Yvonne Voges; Michel Mittelbronn; Tatjana Starzetz; Patrick N. Harter, Scientific Reports (2015) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1038/srep08202